MA52003A - Procédés de traitement de maladies associées au hpv - Google Patents

Procédés de traitement de maladies associées au hpv

Info

Publication number
MA52003A
MA52003A MA052003A MA52003A MA52003A MA 52003 A MA52003 A MA 52003A MA 052003 A MA052003 A MA 052003A MA 52003 A MA52003 A MA 52003A MA 52003 A MA52003 A MA 52003A
Authority
MA
Morocco
Prior art keywords
hpv
diseases associated
treatment methods
diseases
treatment
Prior art date
Application number
MA052003A
Other languages
English (en)
Inventor
Howard Bernstein
Katarina Blagovic
Matt Booty
Kelan Hlavaty
Scott Loughhead
Melissa Myint
Armon R Sharei
Lee Ann Talarico
Alfonso Vicente-Suarez
Original Assignee
Sqz Biotechnologies Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sqz Biotechnologies Co filed Critical Sqz Biotechnologies Co
Publication of MA52003A publication Critical patent/MA52003A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/13—B-cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/39—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by a specific adjuvant, e.g. cytokines or CpG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/55—Lung
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
MA052003A 2018-03-12 2019-03-11 Procédés de traitement de maladies associées au hpv MA52003A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862641988P 2018-03-12 2018-03-12
US201962794517P 2019-01-18 2019-01-18
US201962812225P 2019-02-28 2019-02-28

Publications (1)

Publication Number Publication Date
MA52003A true MA52003A (fr) 2021-01-20

Family

ID=65904594

Family Applications (1)

Application Number Title Priority Date Filing Date
MA052003A MA52003A (fr) 2018-03-12 2019-03-11 Procédés de traitement de maladies associées au hpv

Country Status (18)

Country Link
US (1) US20210038709A1 (fr)
EP (1) EP3765073A2 (fr)
JP (1) JP2021517895A (fr)
KR (1) KR20200130371A (fr)
CN (1) CN112105383A (fr)
AU (1) AU2019234549B2 (fr)
BR (1) BR112020018609A2 (fr)
CA (1) CA3093826A1 (fr)
CO (1) CO2020012583A2 (fr)
CR (1) CR20200461A (fr)
IL (1) IL277190B1 (fr)
MA (1) MA52003A (fr)
MX (1) MX2020009441A (fr)
PE (1) PE20201201A1 (fr)
PH (1) PH12020551437A1 (fr)
SG (1) SG11202008863XA (fr)
TW (1) TW202003025A (fr)
WO (1) WO2019178005A2 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11613759B2 (en) 2015-09-04 2023-03-28 Sqz Biotechnologies Company Intracellular delivery of biomolecules to cells comprising a cell wall
JP7602702B2 (ja) 2016-05-03 2024-12-19 ステムセル テクノロジーズ カナダ インコーポレーテッド 寛容性を誘導するための生体分子の細胞内送達
EP3765068A2 (fr) * 2018-03-12 2021-01-20 SQZ Biotechnologies Company Administration intracellulaire de biomolécules pour modifier une réponse immunitaire
KR20210134353A (ko) 2019-02-28 2021-11-09 에스큐지 바이오테크놀로지스 컴퍼니 면역 반응을 변형시키기 위한 pbmc로의 생체분자의 전달
EP3953039B1 (fr) 2019-04-08 2025-09-10 Stemcell Technologies Canada Inc. Cartouche destinée à être utilisée dans un système de livraison d'une charge utile dans une cellule
WO2020232125A1 (fr) 2019-05-14 2020-11-19 Prometheus Biosciences, Inc. Méthodes, systèmes et dispositifs de sélection de patient tl1a
CN112007149A (zh) * 2019-05-29 2020-12-01 思格(苏州)生物科技有限公司 一种新型复合免疫佐剂及其应用
CN110846318A (zh) * 2019-11-29 2020-02-28 华中科技大学同济医学院附属同济医院 治疗hpv感染的纳米粒制剂中新的靶向序列以及新pbae的制备方法
US20230181712A1 (en) 2020-05-11 2023-06-15 Hoffmann-La Roche Inc. Combination therapy with modified pbmcs and an immunoconjugate
EP4206215A4 (fr) * 2020-07-24 2024-10-23 West China Hospital of Sichuan University Vaccin allogénique à lymphocytes b ciblant veb et son procédé de préparation
WO2022026621A1 (fr) 2020-07-29 2022-02-03 Sqz Biotechnologies Company Procédés pour stimuler des réponses immunitaires à un ras mutant à l'aide de cellules anucléées
EP4188428A1 (fr) 2020-07-29 2023-06-07 SQZ Biotechnologies Company Méthodes pour stimuler des réponses immunitaires à un ras mutant à l'aide de cellules nucléées
KR20230079066A (ko) * 2020-09-02 2023-06-05 에스큐지 바이오테크놀로지스 컴퍼니 유핵 세포를 사용하여 단백질에 대한 hla-불문 면역 반응을 자극하는 방법
JP2024503277A (ja) 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー 活性化抗原担体の製剤
JP2024503279A (ja) 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー Ｐｂｍｃの凍結保存のための製剤
EP4271408A1 (fr) * 2020-12-29 2023-11-08 SQZ Biotechnologies Company Méthodes de traitement de cancers par activation de porteurs d'antigène
JP2024503278A (ja) * 2020-12-29 2024-01-25 スクイーズ バイオテクノロジーズ カンパニー 修飾ｐｂｍｃを用いたがんの治療方法
WO2023010090A1 (fr) 2021-07-29 2023-02-02 Sqz Biotechnologies Company Procédés pour générer des lymphocytes infiltrant les tumeurs améliorés par administration microfluidique
WO2023087009A1 (fr) 2021-11-11 2023-05-19 Sqz Biotechnologies Company Procédés pour générer des lymphocytes infiltrant les tumeurs améliorés par administration microfluidique
WO2023196884A1 (fr) 2022-04-06 2023-10-12 Juno Therapeutics, Inc. Dosage pour la détection du papillomavirus humain (vph) de type 16 (hpv-16)
WO2024026491A2 (fr) 2022-07-28 2024-02-01 Sqz Biotechnologies Company Formulations de cellules présentatrices d'antigène améliorées
CN119894529A (zh) 2022-07-28 2025-04-25 加拿大干细胞技术公司 使用增强型抗原呈递细胞治疗癌症的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008046251A1 (fr) * 2006-10-19 2008-04-24 Sunbio Biotech Pharmaceuticals(Tianjin) Co., Ltd. Protéines hybrides contenant un domaine n de la calréticuline humaine et des protéines e6 ou e7 du papillomavirus humain de type 16, et utilisations associées
AU2008269721B2 (en) * 2007-05-31 2013-01-10 Academisch Ziekenhuis Leiden H.O.D.N. Lumc Intradermal HPV peptide vaccination
JP5797190B2 (ja) * 2009-05-15 2015-10-21 アイ アール エックス セーラピューティクス， インコーポレイテッド ワクチン免疫療法
RU2656156C2 (ru) 2011-10-17 2018-05-31 Массачусетс Инститьют Оф Текнолоджи Внутриклеточная доставка
AU2014290288B2 (en) * 2013-07-15 2018-03-01 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E6 T cell receptors
RU2739794C2 (ru) * 2014-10-31 2020-12-28 Массачусетс Инститьют Оф Текнолоджи Доставка биомолекул в клетки иммунной системы
JP6325751B2 (ja) * 2014-11-04 2018-05-16 ヤンセン ファッシンズ アンド プリベンション ベーフェーＪａｎｓｓｅｎ Ｖａｃｃｉｎｅｓ ＆ Ｐｒｅｖｅｎｔｉｏｎ Ｂ．Ｖ． 治療用ｈｐｖ１６ワクチン
PL3344747T3 (pl) * 2015-09-04 2023-06-19 Sqz Biotechnologies Company Wewnątrzkomórkowe dostarczanie biocząsteczek za pośrednictwem powierzchni z porami
US20190017072A1 (en) * 2016-01-12 2019-01-17 Sqz Biotechnologies Company Intracellular delivery of complexes
CN112574317B (zh) * 2017-01-24 2023-12-05 南京益康生物医药有限公司 一种重组蛋白及药物组合物与应用

Also Published As

Publication number Publication date
WO2019178005A3 (fr) 2019-10-17
US20210038709A1 (en) 2021-02-11
PE20201201A1 (es) 2020-11-11
CA3093826A1 (fr) 2019-09-19
TW202003025A (zh) 2020-01-16
JP2021517895A (ja) 2021-07-29
KR20200130371A (ko) 2020-11-18
BR112020018609A2 (pt) 2020-12-29
RU2020132524A (ru) 2022-04-13
EP3765073A2 (fr) 2021-01-20
WO2019178005A2 (fr) 2019-09-19
CO2020012583A2 (es) 2020-10-30
MX2020009441A (es) 2021-01-08
AU2019234549B2 (en) 2026-02-12
SG11202008863XA (en) 2020-10-29
IL277190B1 (en) 2025-12-01
CN112105383A (zh) 2020-12-18
IL277190A (en) 2020-10-29
CR20200461A (es) 2021-03-11
AU2019234549A1 (en) 2020-10-08
PH12020551437A1 (en) 2021-09-06

Similar Documents

Publication Publication Date Title
MA52003A (fr) Procédés de traitement de maladies associées au hpv
EP3463577A4 (fr) Compositions et procédés de traitement de maladies associées au papillomavirus humain (pvh)
MA49767A (fr) Conjugués de cytokine pour le traitement de maladies auto-immunes
MA50056A (fr) Procédés de traitement de tumeur
EP3426250A4 (fr) Procédés de traitement
EP3448875A4 (fr) Compositions pour le traitement de maladies
EP3448987A4 (fr) Compositions pour le traitement de maladies
EP3601536A4 (fr) Procédés de traitement
EP3370703A4 (fr) Combinaison de gemcabène pour le traitement de maladies cardiovasculaires
LT3556775T (lt) Anti-lag-3 antikūnai, skirti hematologinių piktybinių susirgimų gydymui
EP3548039A4 (fr) Méthodes de traitement de maladies associées au stress mitochondrial
MA52789A (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA54077A (fr) Polythérapie pour le traitement de maladies hématologiques
EP3592224A4 (fr) Méthode permettant de surveiller le traitement de maladies neuropsychiatriques
EP3288565A4 (fr) Composition de matrice extracellulaire pour le traitement du cancer ou des maladies immunologiques
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3749064A4 (fr) Machine de traitement au plasma
EP3866777A4 (fr) Polythérapie pour le traitement de maladies inflammatoires
EP3347492A4 (fr) Procédés pour le diagnostic histologique et le traitement de maladies
EP3630101A4 (fr) Méthodes de traitement de maladies
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
EP3481958A4 (fr) Procédés et compositions de traitement de troubles et de maladies impliquant rdh12
MA53614A (fr) Protéine pour le traitement de maladies inflammatoires
EP4017349A4 (fr) Appareil thérapeutique